Blood group genotyping in multi-transfused patients

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Aim. To assess the possibility of using blood group genotyping in recipients who received transfusions for 3 months.

Methods. The study included blood samples from 95 patients who received 3 or more erythrocyte transfusions within 3 months. The patients had the following diagnoses: multiple myeloma (n=7), beta thalassemia (n=4), non-Hodgkin's lymphomas (n=11), chronic myeloid leukemia (n=16), primary myelofibrosis (n=9), myelodysplastic syndrome (n=22), acute leukemia (n=21), aplastic anemia (n=5). Red blood cells phenotyping was performed in Diaclon Rh Subgroups+K Gel Cards. The Rh and Kell genotyping was performed by using RBC SSP-PCR kits — FluoGene vERYfy (Inno-train Diagnostics, Germany). The standard RHD/RHCE alleles, as well as polymorphisms associated with KEL1/KEL2 [T698C (Met198Thr)] of the KEL gene were genotyped.

Results. The concordance rate between serological and molecular genetic typing of RhCE and Kell blood groups for donors was 100%, while the patient´s results were discordant in 45.3% of cases. Discrepancies in antigens of the Rh system were registered in 41 patients: one antigen of the Rh system — in 30 patients, two — in 9 patients. Ten patients who had been previously phenotyped as RhCc were genotyped as RHCE*CC. 2 patients who had been previously phenotyped as Rhee were genotyped as RHCE*EE. In 2 patients, antigens D and C were not detected in the phenotype but were identified in the genotype. Discrepancies in antigen K were recorded in 2 patients, and the antigen was absent in the phenotype but was present in the genotype. The genotyping results were confirmed by serological typing at subsequent hospitalizations.

Сonclusion. Blood group genotyping is a useful adjunct to traditional methods when serological typing is limited.

Full Text

Restricted Access

About the authors

N V Mineeva

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: izoserologia@mail.ru
ORCID iD: 0000-0001-7137-8877
Russian Federation, Saint ­Petersburg, Russia

I I Krobinets

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Author for correspondence.
Email: transfusion_spb@mail.ru
ORCID iD: 0000-0002-6404-2387
Russian Federation, Saint ­Petersburg, Russia

S V Gavrovskaya

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: izoserologia@mail.ru
Russian Federation, Saint ­Petersburg, Russia

N N Bodrova

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: izoserologia@mail.ru
Russian Federation, Saint ­Petersburg, Russia

E A Sisoeva

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: izoserologia@mail.ru
ORCID iD: 0000-0002-9465-4704
Russian Federation, Saint ­Petersburg, Russia

A V Chechetkin

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: bloodscience@mail.ru
ORCID iD: 0000-0002-7569-0697
Russian Federation, Saint ­Petersburg, Russia

S S Bessmeltsev

Russian Research Institute of Hematology and Transfusiology Federal medical biological agency

Email: bessmeltsev@yandex.ru
ORCID iD: 0000-0001-7280-7100
Russian Federation, Saint ­Petersburg, Russia

References

  1. Anstee D.J. Red cell genotyping and future of pretransfusion testing. Blood. 2009; 114: 248–256. doi: 10.1182/blood-2008-11-146860.
  2. Reid M.E. Transfusion in the age of molecular diagnostics. Hematology. 2009; 14: 171–177. doi: 10.1182/asheducation-2009.1.171.
  3. Scharberg E.A., Richter E. Red cell antigen testing. ISBT Sci. Series. 2015; 10: 5–11. doi: 10.1111/voxs.12134.
  4. Nambiar R.K., Narayanan G., Prakash N.P., Vijaya­lakshmi K. Blood group change in acute myeloid leukemia. Proceedings (Baylor University. Medical Center). 2017; 30: 74–75. doi: 10.1080/08998280.2017.11929536.
  5. Chapuy C.I., Nicholson R.T., Aguad M.D., Chapuy B., Laubach J.P., Richardson P.G., Doshi P., Kaufman R.M. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015; 55: 1545–1554. doi: 10.1111/trf.13069.
  6. Krobinets I.I., Mineeva N.V., Sysoeva E.A., Chechetkin A.V. Features of interpretation of the results of studies of AB0 and Rhesus antigens and antibodies in patients with hematological diseases. Sibirskiy nauchnyy meditsinskiy zhurnal. 2020; 40 (5): 66–72. (In Russ.) doi: 10.15372/SSMJ20200507.
  7. Bakanay S.M., Ozturk A., Ileri T., Ince E., Yavasoglu S., Akar N., Uysal Z., Arslan O. Blood group genotyping in multi-transfused patients. Transfusion and Apheresis Sci. 2013; 48: 257–261. DOI: 110.1016/j.transci.2013.01.009.
  8. Butina E.V., Meneeva N.V., Zaitseva G.A., Poponina E.A., Yovdiy A.V. Red blood cell alloimmunization in patients with hematology/oncology disorders. Transfuziologiya. 2019; 21 (2): 27–34. (In Russ.)
  9. Wang L.Y., Liang D.C., Liu H.C., Chang F.C., Wang C.L., Chan Y.S., Lin M. Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan. Transfus. Med. 2006; 16: 200–203. doi: 10.1111/j.1365-3148.2006.00656.x.
  10. Karimi M., Nikrooz P., Kashef S., Jamalian N., Davatolhagh Z. RBC alloimmunization in blood transfusion-dependent beta-thalassemia patients in southern Iran. Int. J. Lab. Hematol. 2007; 29: 321–326. doi: 10.1111/j.1365-2257.2006.00856.x.
  11. Mineeva N.V., Pashkova I.A., Krobinets I.I., Sysoeva E.A. Allosensibilisation to erythrocyte antigens. Onko­gematologiya. 2015; 10 (4): 60–65. (In Russ.) doi: 10.17650/1818-8346-2015-10-4-60-65.
  12. Kalandarov R.S., Golovkina L.L., Vasilieva M.N., Stremouchova A.G., Pushkina T.D., Atroshchenko G.V., Parovichnikova E.N. Genotyping of AB0 and Rh systems blood groups in patients after multiple hemotransfusions. Onkogematologiya. 2017; 12 (2): 70–79. (In Russ.) doi: 10.17650/1818-8346-2017-12-2-70-79.
  13. Belsito A., Costa D., Fioritoet C., De Iorio G., Casamassimi A., Perrotta S., Napoli C. Erythrocyte genotyping for transfusion-dependent patients at the Azienda Universitaria Policlinico of Naples. Transfusion and Apheresis Sci. 2015; 52: 72–77. doi: 10.1016/j.transci.2014.12.006.
  14. Castilho L., Rios M., Bianco C., Pellegrino J.Jr., Alberto F.L., Saad S.T.O., Costa F.F. DNA-based typing of blood groups for the management of multiply-transfused sickle cell disease patients. Transfusion. 2002; 42: 232–238. doi: 10.1046/j.1537-2995.2002.00029.x.
  15. Remeikiene D., Ugenskiene R., Inciura A., Savukaityte A., Raulinaityte D., Skrodeniene E., Simoliuniene R., Juozaityte E. Duffy and Kidd genotyping facilitates pretransfusion testing in patients undergoing long-term transfusion therapy. Turk. J. Haematol. 2014; 31: 367–373. doi: 10.4274/tjh.2013.0075.
  16. Rujirojindakul P., Flegel W.A. Applying molecular immunohaematology to regularly transfused thalassaemic patients in Thailand. Blood Transfus. 2014; 12: 28–35.
  17. Legler T.G., Eber S.W., Lakomek M., Lynen R., Maas J.H., Pekrun A., Repas-Humpe M., Schröter W., Köhler M. Application of RHD and RHCE genotyping for correct blood group determination in chronically transfused patients. Transfusion. 1999; 39: 852–855. doi: 10.1046/j.1537-2995.1999.39080852.x.
  18. Kulkarni S., Choudhary B., Gogri H., Patil S., Manglani M., Sharma R., Madkaikar M. Molecular genoty­ping of clinically important blood group antigens in patients with thalassemia. Indian J. Med. Res. 2018; 148: 713–720. doi: 10.4103/ijmr.IJMR_455_17.
  19. Bessmeltsev S.S., Romanenko N.A. Anemiya pri opukholevykh zabolevaniyakh sistemy krovi. Rukovodstvo dlya vrachey. (Anemia in tumor diseases of the blood system. Hands for doctors.) M.: SIMK. 2017; 228 p. (In Russ.)

© 2021 Eco-Vector





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies